Abstract
Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Current Enzyme Inhibition
Title: Arachidonic Acid Cascade Enzyme Inhibition and Cancer
Volume: 1 Issue: 2
Author(s): J. J. Moreno
Affiliation:
Keywords: prostaglandins, leukotrienes, eicosanoids, cyclooxygenase, lipoxygenase, cell proliferation, cell growth, neoplasia
Abstract: Arachidonic acid (AA) metabolites are lipid signalling mediators that play a central role in a broad array of physiological and pathophysiological processes, including cell proliferation and differentiation. AA metabolism diverges into two main pathways, the cyclooxygenase (COX) pathway, which leads to prostaglandin and thromboxane production, and the lipoxygenase (LOX) pathway, which leads to the leukotriene and hydroxyeicosatetraenoic acid production. These inflammatory molecules exert profound biological effects that enhance the development and progression of human cancers. A large number of synthetic drugs and natural molecules inhibit the enzymes involved in these pathways and thus prevent, delay or reverse inflammation. They may also prove useful in the chemoprevention of cancer. These studies have primarily used non-steroidal anti-inflammatory drugs, which block the COX pathway. Recent pre-clinical studies indicate that the LOX pathway is also a key target for cancer prevention strategy. This article reviews the role of COX and LOX inhibitors in cell proliferation and cancer.
Export Options
About this article
Cite this article as:
Moreno J. J., Arachidonic Acid Cascade Enzyme Inhibition and Cancer, Current Enzyme Inhibition 2005; 1 (2) . https://dx.doi.org/10.2174/1573408054022261
DOI https://dx.doi.org/10.2174/1573408054022261 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effectiveness and Safety Profile of <i>Ginkgo biloba</i> Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment
CNS & Neurological Disorders - Drug Targets Pathophysiology of Hypertension During Preeclampsia: Role of Inflammatory Cytokines
Current Hypertension Reviews The Metabolism of Methazolamide in Immortalized Human Keratinocytes, HaCaT Cells
Drug Metabolism Letters Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Evaluating the Effects of Oral and Topical Simvastatin in the Treatment of Acne Vulgaris: A Double-blind, Randomized, Placebo-controlled Clinical Trial
Current Clinical Pharmacology Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy
Current Drug Targets NMR Applications for Identifying β-TrCP Protein-Ligand Interactions
Mini-Reviews in Medicinal Chemistry PEGylated Liposomes Incorporated with Nonionic Surfactants as an Apomorphine Delivery System Targeting the Brain: In Vitro Release and In Vivo Real-time Imaging
Current Nanoscience MicroRNAs and Bone Regeneration
Current Genomics Recent Development, Applications, and Perspectives of Mesoporous Silica Particles in Medicine and Biotechnology
Current Medicinal Chemistry Role of SIRT-1 as a Target for Treatment and Prevention of Diabetic Nephropathy: A Review
Current Molecular Pharmacology Heme Oxygenase-1 and Iron in Liver Inflammation: A Complex Alliance
Current Drug Targets Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential
Current Aging Science The cAMP-Dependent Protein Kinase Pathway as Therapeutic Target – Possibilities and Pitfalls
Current Topics in Medicinal Chemistry Vitamin D Analogs as Anti-Carcinogenic Agents
Anti-Cancer Agents in Medicinal Chemistry Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Preface [Hot Topic: Arachidonic Acid Cascade Modulators: The Cyclooxygenase Pathway (Executive Editors: Jean-Michel Dogné / Xavier de Leval)]
Mini-Reviews in Medicinal Chemistry